MDSC: a new potential breakthrough in CAR-T therapy for solid tumors
Open Access
- 19 December 2024
- journal article
- review article
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-17
Abstract
Chimeric antigen receptor T (CAR-T) cell therapy has shown remarkable success in hematologic malignancies but has encountered challenges in effectively treating solid tumors. One major obstacle is the presence of the immunosuppressive tumor microenvironment (TME), which is mainly built by myeloid-derived suppressor cells (MDSCs). Recent studies have shown that MDSCs have a detrimental effect on CAR-T cells due to their potent immunosuppressive capabilities. Targeting MDSCs has shown promising results to enhance CAR-T immunotherapy in preclinical solid tumor models. In this review, we first highlight that MDSCs increase tumor proliferation, transition, angiogenesis and encourage circulating tumor cells (CTCs) extravasation leading to tumor progression and metastasis. Moreover, we describe the main characteristics of the immunosuppressive activities of MDSCs on T cells in TME. Most importantly, we summarize targeting therapeutic strategies of MDSCs in CAR-T therapies against solid tumors. These strategies include (1) therapeutic targeting of MDSCs through small molecule inhibitors and large molecule antibodies; (2) CAR-T targeting cancer cell antigen combination with MDSC modulatory agents; (3) cytokine receptor antigen-targeted CAR-T indirectly or directly targeting MDSCs reshapes TME; (4) modified natural killer (NK) cells expressing activating receptor directly targeting MDSCs; and (5) CAR-T directly targeting MDSC selective antigens. In the near future, we are expected to witness the improvement of CAR-T cell therapies for solid tumors by targeting MDSCs in clinical practice.Keywords
This publication has 149 references indexed in Scilit:
- Tumor microenvironment signaling and therapeutics in cancer progressionCancer Communications, 2023
- Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironmentSeminars in Immunopathology, 2022
- Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapySeminars in Immunopathology, 2022
- Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCsJournal of Cancer Research and Clinical Oncology, 2022
- IL‐1β‐Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up‐regulating Programmed Death Ligand 1 and Colony‐Stimulating Factor 1Hepatology, 2021
- Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapyClinical & Translational Immunology, 2021
- Survival of the fittest: how myeloid-derived suppressor cells survive in the inhospitable tumor microenvironmentCancer Immunology, Immunotherapy, 2019
- Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2–dependent angiogenesis in miceHepatology, 2017
- Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma modelImmunologic Research, 2015
- Polyunsaturated fatty acids promote the expansion of myeloid‐derived suppressor cells by activating the JAK/STAT3 pathwayEuropean Journal of Immunology, 2013